More Me-Too Drugs Please, FDA’s Jenkins Asks Industry
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s top new drug official called out industry’s innovation model, noting that major primary care markets are being left underserved as sponsors focus on precision medicine and rare diseases.